Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, USA.
Cancer Causes Control. 2012 Apr;23(4):609-16. doi: 10.1007/s10552-012-9927-8. Epub 2012 Feb 28.
We examined compliance with and the effects of melatonin supplementation on breast cancer biomarkers (estradiol, insulin-like growth factor I (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the IGF-1/IGFBP-3 ratio) in postmenopausal breast cancer survivors. In a double-blind, placebo-controlled study, postmenopausal women with a prior history of stages 0-III breast cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned to either 3 mg oral melatonin (n = 48) or placebo daily for 4 months. Plasma samples were collected at baseline and after the completion of the intervention. The primary endpoints were compliance and change in estradiol and IGF-1/IGFBP-3 levels. Ninety-five women were randomized (48 to melatonin and 47 to placebo). Eighty-six women (91%) completed the study and provided pre- and postintervention bloods. Melatonin was well tolerated without any grade 3/4 toxicity and compliance was high (89.5%). Overall, among postmenopausal women with a prior history of breast cancer, a 4-month course of 3 mg melatonin daily did not influence circulating estradiol, IGF-1, or IGFBP-3 levels. Compliance was comparable between the two groups. Short-term melatonin treatment did not influence the estradiol and IGF-1/IGBBP-3 levels. Effects of longer courses of melatonin among premenopausal women are unknown. Low baseline estradiol levels in our study population may have hindered the ability to detect any further estradiol-lowering effects of melatonin.
我们研究了褪黑素补充剂对绝经后乳腺癌幸存者的乳腺癌生物标志物（雌二醇、胰岛素样生长因子 I（IGF-1）、胰岛素样生长因子结合蛋白 3（IGFBP-3）和 IGF-1/IGFBP-3 比值）的依从性及其影响。在一项双盲、安慰剂对照研究中，我们将完成包括激素治疗在内的主动癌症治疗（包括激素治疗）的绝经后、有既往 0-III 期乳腺癌病史的女性随机分为每天口服 3 毫克褪黑素（n = 48）或安慰剂组，共 4 个月。在基线和干预完成后采集血浆样本。主要终点是依从性和雌二醇和 IGF-1/IGFBP-3 水平的变化。95 名女性被随机分配（48 名给褪黑素，47 名给安慰剂）。86 名女性（91%）完成了研究并提供了干预前后的血液样本。褪黑素耐受性良好，无任何 3/4 级毒性，且依从性高（89.5%）。总体而言，在有既往乳腺癌病史的绝经后女性中，每天服用 3 毫克褪黑素 4 个月不会影响循环雌二醇、IGF-1 或 IGFBP-3 水平。两组之间的依从性相当。短期褪黑素治疗不会影响雌二醇和 IGF-1/IGBBP-3 水平。在绝经前女性中，更长疗程的褪黑素的影响尚不清楚。我们研究人群中的低基线雌二醇水平可能阻碍了检测褪黑素进一步降低雌二醇作用的能力。
